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uke E. Cameron, MD‡
altimore, Maryland
ince the development of alcohol septal ablation by Sigwart
1) and its increasing adoption, the treatment of symptom-
tic hypertrophic obstructive cardiomyopathy (HOCM)
ith myectomy versus alcohol septal ablation has generated
passion of debate and disagreement not often seen. Of
ourse one contributor to the intensity of this controversy is
hat myectomy is done by surgeons, and ablation by inter-
entional cardiologists: debaters accustomed to disagreeing
ver the best approach to coronary revascularization and
ther issues (2) such as valvular heart disease and the repair
f septal defects. However, participants in the HOCM
ebate have substantial arguments to fuel their passion, and
See page 350
ne important point of contention is the risk of late
rrhythmic events occurring after alcohol ablation. Indeed,
uidelines offered by the American College of Cardiology
nd the European Society of Cardiology (3) have noted with
aution the enthusiastic adoption of alcohol septal ablation,
hich now outnumbers myectomy. Septal ablation, the
rgument goes, produces a myocardial scar in patients who
lready have an arrhythmogenic myocardial substrate,
hereas myectomy does not.
It is worth noting that electrophysiology studies (4,5)
fter septal ablation have not indicated an increased arrhyth-
ogenic substrate, but cases of ventricular tachycardia (6,7)
nd sudden death (8) occurring after septal ablation have
een reported. The specter of re-entrant arrhythmias arising
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.e
From the †Division of Cardiology and the ‡Division of Cardiac Surgery, Johns
opkins Hypertrophic Cardiomyopathy Center, Baltimore, Maryland.rom the septal ablation scar is certainly a plausible concern.
rrhythmia and sudden cardiac death complicate hypertro-
hic cardiomyopathy with or without intervention. For
atients with clinical markers of risk (9) for ventricular
rrhythmias, an implanted defibrillator effectively reduces
he risk (10).
An important contribution to the debate is the report of
aleti et al. (11) in this issue of the Journal. The investiga-
ors performed cardiac magnetic resonance imaging (CMR)
efore and after myectomy (n  24) or alcohol septal
blation (n 24). The findings in and of themselves are not
urprising: with surgical myectomy, a discrete segment of
esection was identified, with minimal to no CMR evidence
f myocardial necrosis, whereas with alcohol ablation, de-
ayed hyperenhancement denoting myocardial infarction
as always seen. This was described as “a large transmural
nfarction, located more inferiorly in the basal septum than
yectomy and usually extending into the right ventricular
ide of the septum at mid-ventricular level” (11).
The pattern of infarction seen by CMR after ablation
akes sense if we imagine the effects of infusing alcohol
nto a septal branch of the proximal left coronary: the
istribution of injury ought to conform to the more or less
edge-shaped distribution of the coronary branch. A wave
ront of profound microvascular obstruction results, with
nfarction of most of the tissue within this zone. We
reviously reported this phenomenon with serial CMR
tudies after alcohol septal ablation (12).
Both septal ablation and myectomy relieve left ventricular
utflow tract (LVOT) obstruction. In the study in this issue
f the Journal, as in other nonrandomized comparisons (13),
yectomy patients were 12 to 13 years younger than septal
blation patients. Because of the very different ages at
resentation for treatment, one must wonder whether the
enotype-phenotype mix differs between the 2 groups. In
omparing the 2 techniques, age, comorbidities, and geno-
ype will affect outcomes. Other comparisons of surgical
yectomy and alcohol septal ablation not controlled for age
ave indicated similar effects on the outflow tract gradient
nd on symptoms (14), but have indicated greater gains in
aximal oxygen consumption during exercise testing (15)
ith myectomy. In 1 age-matched comparison (16), efficacy
including exercise capacity) was not different between the 2
roups, and in that comparison, septal ablation resulted in
ore heart block, whereas myectomy was associated with
ore aortic regurgitation. Without a randomized study, it is
ifficult to assign efficacy differences to the treatments
hemselves, but it is abundantly clear that the site and extent
f myocardial change differ substantially between the 2
reatments. One need only to look at the electrocardiograms
fter treatment to see a difference.
Myectomy is performed through aortotomy while on
ardiopulmonary bypass, with resection of septal myocar-
ium to create a channel expanding the LVOT. The
xperienced Mayo surgeons relieved the LVOT obstruction
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January 23, 2007:358–60 Editorial Commentn all cases; no patient required a permanent pacemaker, and
patient had a stroke 2 weeks after the operation. Left
undle branch block is a frequent consequence of myec-
omy. In contrast, right bundle branch block is a frequent
onsequence of septal ablation (17), and complete heart
lock occurs in some cases. Septal ablation is performed by
dministering ethanol via a small inflated and occlusive
ngioplasty balloon into 1 or more of the coronary branches
upplying the septum (18). Variability (19) in the location,
ize, and distribution of the first septal branch of the left
nterior descending coronary artery adds a dimension of
omplexity to this procedure; septal infarction by ethanol
ay be transmural or may preferentially affect the right or
eft endocardial surfaces of the septum. Before injecting
lcohol, the distribution of the selected branch can be
tudied with echocardiography, while an echocardiographic
ontrast agent is instilled through the balloon, allowing
onfirmation that the region to be infarcted is indeed the
art of the septum that causes the left ventricular outflow
ract obstruction. This technique also avoids injecting alco-
ol into a septal branch supplying other parts of the heart,
ither directly or via collaterals.
Some septal ablation patients had residual obstruction,
nd it is an important finding that most of these had
ontransmural infarction of the right ventricular side of the
eptum, sparing the more proximal basal septum. In theory,
chocardiography with contrast instillation into the selected
ranch should show the distribution of the target vessel.
ne wonders why, in some cases, was the goal of infarcting
he basal septum not achieved? For the cardiologist seeking
erfect results with alcohol septal ablation, these failures
ay be instructive. A number of “failure modes” of contrast
cho-guided septal ablation can be postulated:
. The branch or branches injected with alcohol did not
actually supply the most basal septum, although echo-
cardiography suggested otherwise. Blame echo “bloom-
ing” artifact, or inadequate contrast border definition
and spatial resolution.
. Echocardiography showed sparing of the basal septum
by the contrast instillation, but alcohol injection was
performed anyway. It may have been impossible to
identify a branch supplying that territory. In our expe-
rience, frequently an accessory septal branch (from the
left main coronary, high intermediate branch, or diag-
onal branch) supplies the basal left side of the septum,
and concerted efforts to find and cannulate this branch
are rewarded by successful ablation of the basal septal
bulge. Although it may be tempting to ablate the largest
or easiest septal branch of the LAD, sometimes these
arteries supply the right ventricular side of the septum
(20) or other distant parts of the heart (21,22).
. Echocardiography correctly showed contrast distribu-
tion to the basal septum, but alcohol injection in the
selected branch was ineffective at treating that particular
myocardial segment. Perhaps the different viscosities of
Eechocardiographic contrast versus absolute ethanol ex-
plain the difference in localization. Other percutaneous
approaches to septal ablation have been tried, including
arterial embolization with foam particles (23) and coils
(24); should we consider using a more viscous alcohol
gel?
How large an infarct should we create? One study (25)
uggested that a larger risk area defined by contrast echo-
ardiography predicts a greater risk of heart block and other
omplications and that a smaller risk area predicts fewer
omplications without sacrificing efficacy at relieving ob-
truction. On the other hand, a study (26) of predictors of
reatment failure with septal ablation found that higher
aseline gradient, fewer septal branches injected, lower peak
reatine kinase, and smaller risk area by contrast echocar-
iogram (and higher residual gradient in the catheterization
aboratory) all predicted incomplete relief of obstruction. A
mall randomized study comparing low (1 to 2 ml) and
igher (2 to 4 ml) doses of ethanol found no safety nor
fficacy differences (27). Because continued regression of LV
ypertrophy, including in the septum, has been shown after
eptal ablation (28), most experienced cardiologists have
dopted an approach to alcohol septal ablation relying
eavily on contrast echocardiography guidance for selection
f the most suitable branch and saturation of the target
yocardium with a low dose of slowly infused alcohol.
How should a prudent practitioner (or concerned patient)
hoose a therapy today, in the absence of randomized
omparisons of myectomy with alcohol septal ablation?
oth are effective in most cases (29); crossovers and repeat
rocedures do occur with either. Both have low but finite
isk, and if there is any difference in procedural mortality
etween the 2 approaches, it is small. For old and very old
atients (30), the less invasive approach may be safer;
ortality in surgical series has been reported in the range of
.5% (31) to 3.2% (32) and was associated with age and
emale gender. Mortality in series of patients having alcohol
eptal ablation was 1.2% (33) or 1.3% (34).
The specter of the arrhythmogenic scar deserves further
onsideration. Until we have improved arrhythmia risk
etection tools, a cautious approach considers clinical risk
actors for ventricular arrhythmias and sudden cardiac
eath; when these risk factors are present, defibrillator
mplantation after septal ablation certainly is reasonable.
peculation that myectomy spares the need for a defibrilla-
or is intriguing, but when the stakes are so high, the value
f insurance (in the form of a defibrillator) is hard to
ismiss, no matter which other treatment has been applied.
eprint requests and correspondence: Dr. Alan W. Heldman,
he Johns Hopkins Hypertrophic Cardiomyopathy Center, Car-
egie 565, 600 North Wolfe Street, Baltimore, Maryland 21287.
-mail: aheldman@jhmi.edu.
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